BioNTech reports Q3 revenue of EUR 1.29 billion

BioNTech's Nov. 3, 2026 release says third-quarter revenue was EUR 1,289.2 million, compared with EUR 1,518.9 million a year earlier, and IFRS net profit was EUR 184.5 million, or EUR 0.73 diluted per share. Cash and security investments were EUR 16,163.8 million on Sept. 30, and full-year revenue guidance narrowed to EUR 1.7-1.9 billion from EUR 1.6-1.9 billion. The same release says an exercised Roche/Genentech option generally assigns future collaboration R&D costs to Roche/Genentech from Jan. 1, 2027, while the pancreatic cancer trial continues.